Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05458765 | Project Engage: Oral PrEP Acceptability | PHASE2 | COMPLETED | 330 | — | — | Jun 21, 2022 | Jul 25, 2024 | Jul 29, 2024 | 3 | South Africa, Zimbabwe |
Acceptability will be assessed by discontinuation of study product
| Arm | Type | Description |
|---|---|---|
| F/TAF | ACTIVE_COMPARATOR | daily oral tablet |
| F/TDF | ACTIVE_COMPARATOR | daily oral tablet |
| Name | Type | Description |
|---|---|---|
| emtricitabine/tenofovir alafenamide | DRUG | 200mg/25mg tablet, once daily dosing for 24 weeks |
| Emtricitabine / Tenofovir Disoproxil Oral Tablet | DRUG | 200mg/300mg tablet, once daily dosing for 24 weeks |
Inclusion Criteria: 1. Female, age 15 to 24 years (inclusive) 2. Literate, per local standards, to English and/or local language 3. In general good health, per participant reported medical history and investigator judgement, without any clinically significant systemic disease including but not limi...